Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and Bortezomib in Relapsed/Refractory Non-Hodgkin Lymphoma
NCT00837174Phase 2Withdrawn
- Sponsor
- Houston Methodist Research Institute
- Start
- Jun 2010
- Primary completion
- May 2012
- Modality
- Modified Peptides, Covalent Small Molecules, Classical Binding Small Molecules
01
Overview
A Phase 2 trial of vorinostat, bortezomib in non-Hodgkin lymphoma (NHL), sponsored by Houston Methodist Research Institute. Planned start Jun 2010; status: withdrawn.
02
Drugs
vorinostatbortezomib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00837174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00837174.